Skip to content
Toggle main navigation
EndoForum logo
EndoForum logo
  • Join Today
    Log in
    Select an available language
    EN

    Endocrine News

    Endocrine News provides an in-depth look at trends in the field of endocrinology as well as a closer look at recently published research.

    Filter by category
    All
    Adrenal
    Advocacy
    Bone and Mineral
    Cardiometabolic
    Clinical
    COVID-19
    Diabetes
    Diabetes News and Research
    Diabetes Research Articles
    Early Career Corner
    See all

    Results (27)

    Endocrine Society Scientific Statement Provides Research Roadmap for What’s Next in Obesity Science

    Endocrine Society Scientific Statement Provides Research Roadmap for What’s Next in Obesity Science

    A new Scientific Statement released today by the Endocrine Society highlights the benefits of obesity treatment beyond weight loss, including improvements in overall health and reducing the risk of conditions such as heart disease, sleep apnea and liver disease. Obesity is a complex, chronic disease influenced by biology, genetics, metabolism, the brain, and environmental factors […]The post Endoc
    September 9, 2026
    Experts to Debut Society’s Center on Obesity and New Scientific Statement 

    Experts to Debut Society’s Center on Obesity and New Scientific Statement 

    Members will get a first look at the Society’s new Center on Obesity as well as the Scientific Statement, “Obesity Science, Research Gaps and Opportunities in the New Era of Obesity Medicines,” during a virtual event September 9.  Daniel J. Drucker, MD, a pioneer in the development of GLP-1RA therapies and leader of the writing […]The post Experts to Debut Society’s Center on Obesity and New Scien
    September 4, 2026
    The Hidden Side Effect of Weight-Loss Surgery: Severe Low Blood Sugar

    The Hidden Side Effect of Weight-Loss Surgery: Severe Low Blood Sugar

    At least one in 12 weight-loss surgery patients develop a severe, recurring low blood sugar condition requiring medical intervention, according to a multi-study analysis presented at the ENDO 2026 conference. The condition, known as post-bariatric hypoglycemia (PBH), currently lacks any U.S. Food and Drug Administration-approved treatments. Researchers warn that despite inflicting a heavy financia
    August 17, 2026
    VIDEO: More Than Half of Those Who Stop GLP-1s Restart Within a Year

    VIDEO: More Than Half of Those Who Stop GLP-1s Restart Within a Year

    People who lost weight with GLP-1 anti-obesity medications tended to log fewer daily steps, according to an analysis of the National Institutes of Health’s All of Us Research Program data. Study lead Sajana Maharjan, MD, of HSHS St. John’s Hospital in Springfield, IL, explains the research she presented at ENDO 2026.  “Our study asked two […]The post VIDEO: More Than Half of Those Who Stop GLP-1s
    July 22, 2026
    CPAP Therapy Reverses Low Testosterone in Men with Severe Obesity, Independent of Weight Loss

    CPAP Therapy Reverses Low Testosterone in Men with Severe Obesity, Independent of Weight Loss

    CPAP machines may have a reputation for being unappealing, but according to a recent study, treating sleep issues with them might be the secret to fixing male hormone levels. Severe obstructive sleep apnea syndrome (OSAS) is an independent driver of low testosterone levels in men with severe obesity, but treating the condition with continuous positive […]The post CPAP Therapy Reverses Low Testoste
    July 8, 2026
    Could Moving Obesity Diagnosis Beyond BMI Delay Treatment?

    Could Moving Obesity Diagnosis Beyond BMI Delay Treatment?

    Endocrine Society shares concerns with The Lancet’s obesity frameworkRedefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine Society guideline communication published in The Journal of Clinical Endocrinology & Metabolism.“How obesity is defined has real co
    April 2, 2026
    When the Scale Isn’t the Whole Story: Three Principles for Practicing Person-Centered Obesity Care

    When the Scale Isn’t the Whole Story: Three Principles for Practicing Person-Centered Obesity Care

    Zeb I. Saeed, MD, a member of the steering committee for the Endocrine Society’s Early Career Special Interest Group (SIG), shares with clinicians three patient-centric principles to treating overweight and obesity.Zeb I. Saeed, MDAs endocrinologists, we enter clinical practice having been well trained in the physiology and pharmacological management of obesity, what the BMI cutoffs are, and what
    March 26, 2026
    Heavy Wears the Crown: Obesity’s Link to Dementia

    Heavy Wears the Crown: Obesity’s Link to Dementia

    A recent JCEM paper has indicted obesity as the possible cause of yet another disease – vascular-related dementia. Targeting obesity and hypertension with medications and other weight-loss interventions could prevent developing dementia.In a 2007 paper published in Obesity Reviews, the late Sir David Haslam wrote that the origins of obesity can be traced back 30,000 years. In the paper, “Obesity:
    March 23, 2026
    Moving Forward: The Future of GLP-1 Therapies

    Moving Forward: The Future of GLP-1 Therapies

    The Endocrine Society recently held a virtual Science Writers Conference dedicated to the current landscape and future horizons of GLP-1 therapies, examining new oral formulations and dual and triple agonists. Endocrine News caught up with the two experts who spoke at the conference — Priya Jaisinghani, MD, DABOM and Mehmet Furkan Burak, MD – to learn what’s next for these medications and what the
    March 11, 2026
    Closing the Obesity Diagnosis Gap: A New EHR-Based Measure Could Improve Population Health Outcomes

    Closing the Obesity Diagnosis Gap: A New EHR-Based Measure Could Improve Population Health Outcomes

    A new obesity measure championed by authors of a recent Journal of Clinical Endocrinology & Metabolism paper could move the needle in managing obesity in patients, aligning better with public health priorities and improving patient care overall by integrating obesity recognition into routine clinical practice across specialties.Despite growing awareness of obesity as a chronic disease, many patien
    March 10, 2026
    No Patient Left Behind: Expanding Semaglutide’s Reach

    No Patient Left Behind: Expanding Semaglutide’s Reach

    Recent studies from Endocrine Society journals have shown that GLP-1 RAs are not only successful in reducing obesity, but they have positive impacts on a range of other conditions. From improving taste sensitivity and positive results in a pediatric patient with several comorbidities to being an effective treatment in patients with a variety of psychiatric disorders, these drugs are routinely exce
    March 9, 2026
    Maternal Blood Sugar Levels Linked to Heightened Obesity Risk in Adolescents

    Maternal Blood Sugar Levels Linked to Heightened Obesity Risk in Adolescents

    A significant retrospective cohort study has revealed that even mild levels of glucose intolerance during pregnancy are associated with a higher risk of obesity in children as they reach adolescence. The research, published in The Journal of Clinical Endocrinology & Metabolism, suggests that the in utero environment may play a more critical role in long-term metabolic health than previously unders
    March 4, 2026
    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    Side Effects: Endocrine Society Journals Look at GLP-1RAs and the Positive and Negative Unintended Impacts

    As the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) expands, so too does our knowledge of just what all these medications can do. GLP-1RAs have now been shown to reduce consumption of alcohol and drugs, even treating addictions to gambling and sex, but these medications can also potentially lead to rare but fatal complications of which endocrinologists should be aware.Glucagon-like
    February 19, 2026
    New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

    New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk

    The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system to fight it.Thyroid cancer is the most comm
    February 12, 2026
    Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

    Novo Nordisk’s OASIS 4 Study Validates Daily Oral Pill for Chronic Weight Management

    A new year brings a new therapeutic milestone for weight management: Following its recent U.S. Food and Drug Administration approval, the 25 mg oral semaglutide tablet (brand name: Wegovy), a once-daily pill became available in the United States in early January 2026 for chronic weight management and for reducing the risk of major adverse cardiovascular events in adults living with obesity or over
    February 10, 2026
    New Study Links Combination of Hormone Therapy and Tirzepatide to Greater Weight Loss after Menopause

    New Study Links Combination of Hormone Therapy and Tirzepatide to Greater Weight Loss after Menopause

    A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.Menopause can accelerate age-related weight
    January 29, 2026
    People with Obesity May Have a Higher Risk of Dementia

    People with Obesity May Have a Higher Risk of Dementia

    People with obesity and high blood pressure may face a higher risk of dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism.Dementia is a growing global public health challenge, with no cure currently available. People with dementia experience a severe decline in mental abilities, like memory, thinking and reasoning.The most common forms of dementia are
    January 22, 2026
    EUREKA! The Top Endocrine Science of 2025

    EUREKA! The Top Endocrine Science of 2025

    For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers!For more than
    December 11, 2025
    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes

    New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.The study (the SURPASS-PEDS trial), led by Tamara Hannon,
    December 2, 2025
    Hidden Skeletal Consequences of Adolescent Obesity

    Hidden Skeletal Consequences of Adolescent Obesity

    New research reveals long-term bone health implicationsResearch presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on bone development in this population.In new resear
    November 12, 2025
    Contact
    1 (888) 363-6762
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.